Estramustine phosphate in the treatment of hormone escape prostatic carcinoma - a 3 year follow-up

by Altaf H Syed, Mohd N Akhtar, C Shearing, P R Bollina, D N Tulloch
Published 2003-01-01

Employing a mobile health decision aid to improve decision-making for patients with advanced prostate cancer and their decision partners/proxies: the CHAMPION randomized controlled trial study design

by Lourdes R. Carhuapoma, Winter M. Thayer, Catherine E. Elmore, Jane Gildersleeve, Tanmay Singh, Farah Shaukat, Melissa K. Uveges, Tamryn Gray, Crystal Chu, Daniel Song, Patricia J. Hollen, Jennifer Wenzel, Randy A. Jones
Published 2021-09-01

Programmed death-ligand 1 positive and non-epithelial subgroup in circulating tumor cells predict prognosis and guide the immunotherapy after radical prostatectomy in locally advanced prostate cancer

by L. Ke, Y. Li, Y. Mao, R. Wu, J. He, S. Lu, Y. Qing, Y. Huang, J. Qiu
Published 2020-07-01

Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials

by Peter Iversen, Jan-Erik Damber, Anders Malmberg, Bo-Eric Persson, Laurence Klotz
Published 2016-04-01

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

by Gustavo Werutsky, Fernando Cotait Maluf, Eduardo Henrique Cronemberger, Vinicius Carrera Souza, Suelen Patricia dos Santos Martins, Fábio Peixoto, Oren Smaletz, Fábio Schutz, Daniel Herchenhorn, Telma Santos, Flavio Mavignier Carcano, David Queiroz Muniz, Paulo R. S. Nunes Filho, Facundo Zaffaroni, Carlos Barrios, André Fay
Published 2019-05-01

A review of continuous vs intermittent androgen deprivation therapy: Redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a perpetual dispute

by Zisis Kratiras, Charalampos Konstantinidis, Konstantinos Skriapas
Published 2014-01-01

Estrogen receptor (α and β) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer in an urban Greek...

by Georgios Megas, Michael Chrisofos, Ioannis Anastasiou, Aida Tsitlidou, Theodosia Choreftaki, Charalampos Deliveliotis
Published 2015-02-01

Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac

by Jesús A. Junco, Ranfis Rodríguez, Franklin Fuentes, Idania Baladrón, Maria D. Castro, Lesvia Calzada, Carmen Valenzuela, Eddy Bover, Eulogio Pimentel, Roberto Basulto, Niurka Arteaga, Angel Cid-Arregui, Francisco Sariol, Lourdes González, Liliana Porres-Fong, María Medina, Ayni Rodríguez, A. Hilda Garay, Osvaldo Reyes, Matilde López, Lourdes de Quesada, Allelin Alvarez, Carolina Martínez, Marleny Marrero, Guillermo Molero, Alfredo Guerra, Pedro Rosales, Carlos Capote, Sahily Acosta, Idania Vela, Lina Arzuaga, Ana Campal, Erlán Ruiz, Elier Rubio, Pável Cedeño, María Carmen Sánchez, Pedro Cardoso, Rolando Morán, Yairis Fernández, Magalys Campos, Henio Touduri, Dania Bacardi, Indalecio Feria, Amilcar Ramirez, Karelia Cosme, Pedro López Saura, Maricel Quintana, Verena Muzio, Ricardo Bringas, Marta Ayala, Mario Mendoza, Luis E. Fernández, Adriana Carr, Luis Herrera, Luis Herrera, Gerardo Guillén
Published 2019-02-01

717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy

by Caius Radu, Mark Salvati, Julie Bailis, Katharina Lueckerath, Kyle Current, Johannes Czernin
Published 2020-11-01

Quality of life of patients with hormone-dependent advanced prostate cancer receiving palliative...

by G. Geiges, C. Winter, K. Katzenberger, M. Kübrich
Published 2020-11-01

Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate...

by Hiroji Uemura, Yosuke Koroki, Yuki Iwaki, Keiichiro Imanaka, Takeshi Kambara, Angela Lopez-Gitlitz, Andressa Smith, Hirotsugu Uemura
Published 2020-09-01

When Less Is More: Specific Capture and Analysis of Tumor Exosomes in Plasma Increases the Sensitivity of Liquid Biopsy for Comprehensive Detection of Multiple Androgen Receptor Phenotypes in Advanced Prostate Cancer Patients

by Chiara Foroni, Natasa Zarovni, Laura Bianciardi, Simona Bernardi, Luca Triggiani, Davide Zocco, Marta Venturella, Antonio Chiesi, Francesca Valcamonico, Alfredo Berruti
Published 2020-05-01

Re: A review of continuous vs intermittent androgen deprivation therapy: Redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ?perpetual dispute?

by Zisis Kratiras, Charalampos Konstantinidis, Konstantinos Skriapas
Published 2014-04-01

Genomic predictors for treatment of late stage prostate cancer

by Daniel H Shevrin
Published 2016-01-01

Evaluation of ⁶⁸Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving ¹⁷⁷Lu-PSMA-617 Therapy: A Radiomics Analysis

by Wolfgang Roll, Philipp Schindler, Max Masthoff, Robert Seifert, Katrin Schlack, Martin Bögemann, Lars Stegger, Matthias Weckesser, Kambiz Rahbar
Published 2021-07-01

Correction to: Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label...

by Hiroji Uemura, Yosuke Koroki, Yuki Iwaki, Keiichiro Imanaka, Takeshi Kambara, Angela Lopez-Gitlitz, Andressa Smith, Hirotsugu Uemura
Published 2020-10-01

Patient‐reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase...

by Akira Yokomizo, Hirofumi Koga, Kazuto Ito, Yutaka Takezawa, Motokiyo Komiyama, Kazuo Nishimura, Junji Yonese, Katsuyoshi Hashine, Naoya Masumori, Gaku Arai, Shiro Saito, Mitsuru Shinohara, Nobuaki Shimizu, Atsushi Yamauchi, Takefumi Satoh, Tatsuo Tochigi, Mikio Kobayashi, Hiroyuki Fujimoto, Ken‐ichi Kakimoto, Iwao Fukui, Taiji Tsukamoto, Miwako Nozaki, Katsuyuki Karasawa, Masaru Hasumi, Mikinobu Ohtani, Hiromichi Ishiyama, Masaaki Kuwahara, Masaoki Harada, Yasuo Ohashi, Toshihiko Kotake, Tadao Kakizoe, Kazuhiro Suzuki, Seiji Naito, Hidetoshi Yamanaka, National Research Project on Endocrine‐Radiation Combination Therapy for Locally Advanced Prostate Cancer investigators
Published 2021-05-01

Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional...

by Mladen Solarić, Anders Bjartell, Ursula Thyroff-Friesinger, Davide Meani
Published 2017-06-01

Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21)

by Brian Hayes, Lauren Brady, Gráinne Sheill, Anne-Marie Baird, Emer Guinan, Bryan Stanfill, Jean Dunne, Dean Holden, Tatjana Vlajnic, Orla Casey, Verena Murphy, John Greene, Emma H. Allott, Juliette Hussey, Fidelma Cahill, Mieke Van Hemelrijck, Nicola Peat, Lorelei A. Mucci, Moya Cunningham, Liam Grogan, Thomas Lynch, Rustom P. Manecksha, John McCaffrey, Dearbhaile M. O’Donnell, Orla Sheils, John J. O’Leary, Sarah Rudman, Ray McDermott, Stephen Finn
Published 2021-09-01

The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate...

by Antonio Cassio Assis Pellizzon, João Salvajoli, Paulo Novaes, Maria Maia, Ricardo Fogaroli, Doglas Gides, Rodrigues Horriot
Published 2008-01-01